Literature DB >> 18829548

Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease.

Karim Iskander1, Roberto J Barrios, Anil K Jaiswal.   

Abstract

NAD(P)H:quinone oxidoreductase 1 null (NQO1(-/-)) mice exposed to 3 Gy of gamma-radiation showed an increase in neutrophils, bone marrow hypercellularity, and enlarged lymph nodes and spleen. The spleen showed disrupted follicular structure, loss of red pulp, and granulocyte and megakarocyte invasion. Blood and histologic analysis did not show any sign of infection in mice. These results suggested that exposure of NQO1(-/-) mice to gamma-radiation led to myeloproliferative disease. Radiation-induced myeloproliferative disease was observed in 74% of NQO1(-/-) mice as compared with none in wild-type (WT) mice. NQO1(-/-) mice exposed to gamma-radiation also showed lymphoma tissues (32%) and lung adenocarcinoma (84%). In contrast, only 11% WT mice showed lymphoma and none showed lung adenocarcinoma. Exposure of NQO1(-/-) mice to gamma-radiation resulted in reduced apoptosis in granulocytes and lack of induction of p53, p21, and Bax. NQO1(-/-) mice also showed increased expression of myeloid differentiation factors CCAAT/enhancer binding protein alpha (C/EBPalpha) and Pu.1. Intriguingly, exposure of NQO1(-/-) mice to gamma-radiation failed to induce C/EBPalpha and Pu.1, as was observed in WT mice. These results suggest that decreased p53/apoptosis and increased Pu.1 and C/EBPalpha led to myeloid hyperplasia in NQO1(-/-) mice. The lack of induction of apoptosis and differentiation contributed to radiation-induced myeloproliferative disease in NQO1(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829548      PMCID: PMC2597166          DOI: 10.1158/0008-5472.CAN-08-0766

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism.

Authors:  J K Wiencke; M R Spitz; A McMillan; K T Kelsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-02       Impact factor: 4.254

2.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice.

Authors:  D E Zhang; P Zhang; N D Wang; C J Hetherington; G J Darlington; D G Tenen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue.

Authors:  A Gaikwad; D J Long; J L Stringer; A K Jaiswal
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

4.  Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.

Authors:  K Lezon-Geyda; V Najfeld; E M Johnson
Journal:  Leukemia       Date:  2001-06       Impact factor: 11.528

5.  Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking.

Authors:  E A Rosvold; K A McGlynn; E D Lustbader; K H Buetow
Journal:  Pharmacogenetics       Date:  1995-08

6.  Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone.

Authors:  N Rothman; M T Smith; R B Hayes; R D Traver; B Hoener; S Campleman; G L Li; M Dosemeci; M Linet; L Zhang; L Xi; S Wacholder; W Lu; K B Meyer; N Titenko-Holland; J T Stewart; S Yin; D Ross
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

7.  NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin.

Authors:  D J Long; R L Waikel; X J Wang; D R Roop; A K Jaiswal
Journal:  J Natl Cancer Inst       Date:  2001-08-01       Impact factor: 13.506

8.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

Authors:  D B Zimonjic; J L Pollock; P Westervelt; N C Popescu; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

9.  Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

Authors:  K T Kelsey; D Ross; R D Traver; D C Christiani; Z F Zuo; M R Spitz; M Wang; X Xu; B K Lee; B S Schwartz; J K Wiencke
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.

Authors:  D Siegel; A Anwar; S L Winski; J K Kepa; K L Zolman; D Ross
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

View more
  12 in total

1.  Benzene toxicity: The role of the susceptibility factor NQO1 in bone marrow endothelial cell signaling and function.

Authors:  David Ross; Hongfei Zhou; David Siegel
Journal:  Chem Biol Interact       Date:  2010-10-21       Impact factor: 5.192

Review 2.  Regulation of Nrf2-an update.

Authors:  Suryakant K Niture; Raju Khatri; Anil K Jaiswal
Journal:  Free Radic Biol Med       Date:  2013-02-19       Impact factor: 7.376

3.  Retraction: NRH:Quinone Oxidoreductase 2-Deficient Mice Are Highly Susceptible to Radiation-induced B-Cell Lymphomas.

Authors:  Karim Iskander; Roberto J Barrios; Anil K Jaiswal
Journal:  Clin Cancer Res       Date:  2018-11-01       Impact factor: 12.531

4.  Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis.

Authors:  Staci L Haney; Ryan A Hlady; Jana Opavska; David Klinkebiel; Samuel J Pirruccello; Samikshan Dutta; Kaustubh Datta; Melanie A Simpson; Lizhao Wu; Rene Opavsky
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

5.  A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane-treated colon cancer cells.

Authors:  Gavin S Johnson; Jia Li; Laura M Beaver; W Mohaiza Dashwood; Deqiang Sun; Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Mol Nutr Food Res       Date:  2017-01-03       Impact factor: 5.914

6.  Tungsten-induced carcinogenesis in human bronchial epithelial cells.

Authors:  Freda Laulicht; Jason Brocato; Laura Cartularo; Joshua Vaughan; Feng Wu; Thomas Kluz; Hong Sun; Betul Akgol Oksuz; Steven Shen; Massimiliano Peana; Serenella Medici; Maria Antonietta Zoroddu; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2015-07-09       Impact factor: 4.219

7.  NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.

Authors:  Manali Dimri; Ashley Humphries; Archana Laknaur; Sawsan Elattar; Tae Jin Lee; Ashok Sharma; Ravindra Kolhe; Ande Satyanarayana
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

8.  NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomas.

Authors:  Karim Iskander; Roberto J Barrios; Anil K Jaiswal
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

9.  NRH:quinone oxidoreductase 2 (NQO2) protein competes with the 20 S proteasome to stabilize transcription factor CCAAT enhancer-binding protein α (C/EBPα), leading to protection against γ radiation-induced myeloproliferative disease.

Authors:  Junkang Xu; Brad Allen Patrick; Anil K Jaiswal
Journal:  J Biol Chem       Date:  2013-10-19       Impact factor: 5.157

10.  NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease.

Authors:  Junkang Xu; Anil K Jaiswal
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.